Skip to content

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General

Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth: A Randomized Clinical Trial

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04104789
Enrollment
0
Registered
2019-09-26
Start date
2020-09-30
Completion date
2021-10-31
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apical Periodontitis, Caries,Dental

Keywords

Cavities, crowns

Brief summary

The primary goal of the study is to compare the success rates of pulpal anesthesia (defined as ability to complete the intended dental procedure without the need for rescue anesthesia) between Kovanaze nasal mist and Articaine needle anesthesia.

Detailed description

In June 2016, an intranasal delivery system of local anesthesia called Kovanaze, gained FDA approval. Kovanaze is available as a 0.2 ml metered spray and is intended to achieve pulpal anesthesia of 5 maxillary teeth on either side of the face. With the ability to avoid the traditional painful injection Kovanaze offers promise in the field of maxillary anesthesia and this study intends to: 1. Compare Kovanaze to conventional needle anesthetic in adults 2. Evaluate patient anxiety, tolerance and acceptability of Kovanaze in patients undergoing dental procedures

Interventions

Intra-nasal local anesthetic

Local anesthetic

Sponsors

Virginia Commonwealth University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists Class I or II * Preoperative heart rate of 55 to 100 beats per minute * Maximum blood pressure reading of 166/100 mmHg * Treatment for a pathology in the maxillary anterior tooth or premolar that requires administering local anesthesia * Adults who require restorations in the maxillary teeth that would need local anesthesia

Exclusion criteria

* Inadequately controlled thyroid disease * Five or more nosebleeds in the past month * Known allergy to any study drug or para-aminobenzoic acid * History of methemoglobinemia * Taking monoamine oxidase inhibitors, tricyclic antidepressants (i.e. amitriptyline), or non-selective beta adrenergic antagonists (i.e. propranolol); * Taking oxymetazoline-containing products (i.e., Afrin) in the last 24 hours.

Design outcomes

Primary

MeasureTime frameDescription
Success rate of pupal anesthesiaimmediately after dental procedure, an average of 3 hours% dental procedures completed without the need for rescue anesthesia

Secondary

MeasureTime frameDescription
Change in Anxiety levelfrom baseline to immediately after dental procedureModified Dental Anxiety Scale - 5 item questionnaire assessing dental visit related anxiety on a 5 point scale ranging from 1 (not anxious) to 5 (extremely anxious). Scores range from 5 to 25.
Change in Blood pressurefrom baseline to immediately after dental proceduresystolic and diastolic blood pressure will be assessed before and after the dental procedure
Change in heart ratefrom baseline to immediately after dental procedure
Spread of anesthesiaimmediately after dental procedure, an average of 3 hoursNumber of teeth anesthetized in maxillary arch
Satisfaction with Kovanazeimmediately after dental procedure, an average of 3 hours8-item questionnaire with a variety of scales designed to measure satisfaction with Kovanaze
Number of post treatment anesthesia side effects24 hoursPhone survey asking about any side effects experienced from the anesthesia
Change in painfrom baseline to immediately after dental procedureHeft-Parker visual analog scale rated from none (0mm) to maximum possible (170mm)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026